Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles

Novo Nordisk reported Q2 2025 earnings of $0.97 per ADR, surpassing estimates, but revenues of $11.68 billion missed consensus despite an 18% year-over-year increase at constant exchange rates, largely due to a slowdown in its key GLP-1 obesity drug, Wegovy. This performance, coupled with persistent challenges from illegal compounded versions in the U.S. and intensifying competition from Eli Lilly, led the company to cut its 2025 sales growth guidance to 8-14% and operating profit growth to 10-16% (CER). Despite a significant year-to-date share decline, Novo Nordisk is strategically pursuing label expansions for its semaglutide drugs, including an oral Wegovy, and leveraging initiatives like exclusive formulary coverage to bolster its market leadership.

Analysis

Novo Nordisk's second-quarter 2025 results present a challenging narrative despite a headline earnings beat of $0.97 per ADR against a $0.93 estimate. The core issue is a revenue miss ($11.68 billion vs. $11.79 billion consensus) and, more critically, a significant reduction in full-year 2025 guidance. The company slashed its sales growth forecast from 13-21% to 8-14% and its operating profit growth from 16-24% to 10-16% at CER. This revision is a direct consequence of weakening momentum in its flagship GLP-1 franchise. Wegovy sales, while up 75% year-over-year, are experiencing a decelerating growth rate, explicitly impacted by the persistent availability of illegal compounded alternatives and slower-than-anticipated uptake in the U.S. market. Compounding this pressure is intensifying competition from Eli Lilly's Mounjaro and Zepbound, which has contributed to a 1.4% decline in Novo Nordisk's global diabetes market share over the past year to 32.6%. The company's 45.1% year-to-date share price plunge reflects these material headwinds, which overshadow strong performance in its Rare Disease segment (+28%) and rising promotional costs (+19% in S&D) required to defend its market position. Future growth now hinges on strategic initiatives like the exclusive CVS formulary coverage and potential pipeline catalysts, most notably the FDA's year-end decision on an oral formulation of Wegovy.

Key Decisions for Investors

• Investors should recognize that the significant 2025 guidance cut signals a material deterioration in the growth outlook for key products Wegovy and Ozempic, warranting a cautious or bearish stance in the near term.
• Closely monitor competitive pressures from Eli Lilly, including its upcoming earnings report and market share data, as this is a primary driver of Novo Nordisk's current underperformance and future growth prospects.
• While the stock has plunged 45.1% year-to-date, key catalysts to watch before considering a position are the FDA's decision on oral Wegovy by year-end and the tangible sales impact from the new exclusive CVS formulary coverage which began July 1st.
• Evaluate the company's ability to combat illegal compounded drugs and manage rising sales and distribution costs, as these factors are directly eroding profitability and constraining the growth of the high-margin obesity care segment.